Promising Developments in Alzheimer’s and Parkinson’s Research at the AD/PD™ 2023 Conference in Gothenburg
The International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders - AD/PD™ is a Kenes (PCO) Original Event.
The 16th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2023) opened on March 28th in the Swedish Exhibition & Congress Centre with a welcome address by Her Majesty Queen Silvia of Sweden, who highlighted the importance of research in Alzheimer’s and Parkinson’s diseases and expressed her gratitude for the efforts of the scientific community to find effective treatments for these debilitating conditions.
This premier scientific meeting concluded on the 1st of April after five empowering days of presentations, workshops, and networking sessions. AD/PD™ 2023 brought together 4,120 participants from around the world – 3,289 onsite and 831 online – including leading scientists, clinicians, and industry representatives, to discuss the latest advances in Alzheimer’s, Parkinson’s, and related diseases.
AD/PD™ 2023 featured 1,019 talks (673 onsite and 346 by online participants), 112 symposia, eight industry symposia, seven plenary presentations and six forum discussions. The lectures covered a wide range of topics pertaining to Alzheimer’s, Parkinson’s, and related neurodegenerative diseases, encompassing genetics, biomarkers, cutting-edge technologies, clinical trials, and therapeutics.
Some of the key highlights of the Conference included:
- Advances in understanding the genetic and environmental factors that contribute to the development of Alzheimer’s and Parkinson’s diseases.
- New developments in the use of biomarkers for early detection and diagnosis of Alzheimer’s and Parkinson’s diseases.
- Progress in the development of disease-modifying therapies for Alzheimer’s and Parkinson’s diseases, including drugs targeting beta-amyloid, tau, and alpha-synuclein.
- Emerging technologies, such as virtual reality and artificial intelligence, for improving the diagnosis and treatment of Alzheimer’s and Parkinson’s diseases.
“We are thrilled with the outcome of this year’s AD/PD™ Conference”, said Professor Abraham Fisher, President of AD/PD™. He added: “The Conference has provided a unique platform for sharing new research findings and promoting collaborations among scientists and clinicians worldwide. We are confident that the insights and innovations presented at this Conference will accelerate progress towards finding effective treatments for Alzheimer’s and Parkinson’s diseases.”
The next AD/PD™ Conference will take place on March 5 – 9, 2024 in Lisbon, Portugal.
The International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) is a groundbreaking series of annual Conferences initiated by the Professional Conference Organiser (PCO) Kenes Group, that bring together leading scientists, clinicians, and industry experts to discuss the latest advances and research in Alzheimer’s and Parkinson’s diseases, and related neurological disorders.
The Conference remains at the forefront of unravelling the mechanisms and improving the treatment of Alzheimer’s, Parkinson’s, and other related neurodegenerative diseases. AD/PD™ Conferences uniquely combine distinct neurodegenerative disorders in one setting and examine their similarities and differences with a strong focus on disease mechanisms, diagnosis, prevention, and therapy.
More information: https://adpd.kenes.com/
Daily highlights – Videos: https://adpd.kenes.com/daily-videos/